Document is current

Article History

Received: 3 October 2025

Accepted: 10 December 2025

First Online: 7 January 2026

Declarations

:

: All procedures performed in the CKD-REIN cohort were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration. All legal autorizations were obtained including those from the Comité consultatif sur le traitement de l’information en matière de recherche dans le domaine de la santé (CCTIRS N°12.360) , the Commission nationale de l’informatique et des libertés (CNIL N°DR-2012–469), and from the Kremlin-Bicêtre Comité de protection des personnes (CPP N°IDRCB 2012-A00902-41) . CKD-REIN biological collection is registered in the management application of the COnservation D’Eléments du COrps Humain (CODECOCH N°-2012–1624). The Institut national de la santé et de la recherche médical (Inserm) Institutional Review Board approved the study protocol (IRB00003888). ClinicalTrials.gov Identifier: NCT03381950 (21/12/2017). All participants provided written informed consent.

: Not applicable.

: N.A.P. declare financial support from pharmaceutical companies currently integrating the public-private partnership of the CKD-REIN cohort: GlaxoSmithKline (GSK), Boeringher Ingelheim, and Novo Nordisk; all grants are made to Paris Saclay University. Other authors have nothing to disclose.